Patient Consent Management in Long Term Follow Up Trials
Team: Alice Morgenszttern, Caroline Liu, Gianfranco Lucchesi, Ian Chiang

The Company
AI-powered real world data-driven company for health prediction and diagnosis
Manages clinical trials for cancer drugs and regulatory drug prescriptions
❖ $150 million raised
❖ $1.9 billion valuation

Long-term Follow-up Trials
Understanding the long term effects of a health intervention
❖ Current TAM: $36 million (0.12% of on-going clinical trials)
❖ Estimated TAM in 2030: $235 million
❖ Need for specific data and consent tracking processes

The Blockchain
Already used in healthcare for patient tokenization. Allows for the creation of a smart contract that can automatically enforce its terms.
❖ Secured
❖ Decentralized
❖ Immutable
❖ Customizable

The Solution
Four stakeholders:
❖ Concert AI
❖ Sponsor
❖ Patient
❖ Third party
One platform with two interfaces:
❖ Request access to data.
❖ Manage patient consent through a smart contract, potentially combining with patient token and NFTs

Business plan
Two possibilities: build in-house or partner.
In both cases, the biggest costs are probably not associated with upfront investment (as it’s a common use of the blockchain), but with integration into existing solutions and maintenance.